Landmark Trials in Heart Failure Management
Key randomized controlled trials that shaped the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Presented with population, intervention, primary outcome, and clinical significance.
How These Trials Shaped the 2022 HF Guideline
- SGLT2 inhibitors established as foundational GDMT across the LVEF spectrum (DAPA-HF, EMPEROR-Reduced, EMPEROR-Preserved, DELIVER)
- ARNi preferred over ACEi/ARB in HFrEF (PARADIGM-HF)
- MRA benefit extended to mild HFrEF (EMPHASIS-HF confirmed RALES findings in NYHA II)
- First disease-modifying therapy for HFpEF via SGLT2 inhibitors (EMPEROR-Preserved, DELIVER)
- Cardiac amyloidosis formally integrated into HF management (ATTR-ACT)
- CRT improves outcomes in mild HF with LBBB (MADIT-CRT, COMPANION)
Watch for:
- GLP-1 RA trials in HFpEF with obesity (STEP-HFpEF, SELECT-HF)
- Novel myosin activators and cardiac contractility modulation data
- Gene therapy and RNA-based approaches for hereditary amyloidosis
HFrEF Guideline-Directed Medical Therapy
1NEJMARNi vs ACEiPARADIGM-HF: Sacubitril/Valsartan vs Enalapril in HFrEF
20% reduction in CV death or HF hospitalization; trial stopped early
PARADIGM-HF: Sacubitril/Valsartan vs Enalapril in HFrEF
20% reduction in CV death or HF hospitalization; trial stopped early
Population:8,442 adults with NYHA II-IV HFrEF (LVEF ≤40%, later amended to ≤35%), elevated natriuretic peptides, on stable HF therapy.
Intervention: Sacubitril/valsartan 200 mg twice daily vs enalapril 10 mg twice daily.
Result:20% reduction in CV death or HF hospitalization (HR 0.80, 95% CI 0.73-0.87, p<0.001). 16% reduction in all-cause mortality (HR 0.84, p=0.034). Trial stopped early for overwhelming benefit at 27 months.
Significance: Established ARNi as superior to ACEi in HFrEF. Led to COR 1, LOE A recommendation for ARNi as preferred first-line neurohormonal agent. Changed standard of care from ACEi/ARB to ARNi.
McMurray JJV, et al. N Engl J Med. 2014;371(11):993-1004.
DOI: 10.1056/NEJMoa1409077 →2NEJMSGLT2i in HFrEFDAPA-HF: Dapagliflozin in HFrEF
26% reduction in worsening HF or CV death; benefit regardless of diabetes status
DAPA-HF: Dapagliflozin in HFrEF
26% reduction in worsening HF or CV death; benefit regardless of diabetes status
Population:4,744 adults with NYHA II-IV HFrEF (LVEF ≤40%) on standard therapy, with or without type 2 diabetes.
Intervention: Dapagliflozin 10 mg daily vs placebo on top of standard HF therapy.
Result:26% reduction in worsening HF or CV death (HR 0.74, 95% CI 0.65-0.85, p<0.001). Benefit consistent in patients with and without diabetes. NNT = 21 over 18.2 months.
Significance: First SGLT2i trial in HFrEF showing benefit independent of diabetes. Led to COR 1, LOE A recommendation for SGLT2i as fourth pillar of GDMT.
McMurray JJV, et al. N Engl J Med. 2019;381(21):1995-2008.
DOI: 10.1056/NEJMoa1911303 →3NEJMSGLT2i in HFrEFEMPEROR-Reduced: Empagliflozin in HFrEF
25% reduction in CV death or HF hospitalization; confirmed DAPA-HF findings
EMPEROR-Reduced: Empagliflozin in HFrEF
25% reduction in CV death or HF hospitalization; confirmed DAPA-HF findings
Population:3,730 adults with NYHA II-IV HFrEF (LVEF ≤40%) on standard therapy.
Intervention: Empagliflozin 10 mg daily vs placebo on top of standard HF therapy.
Result:25% reduction in CV death or HF hospitalization (HR 0.75, 95% CI 0.65-0.86, p<0.001). 30% reduction in HF hospitalizations. Slowed eGFR decline.
Significance: Confirmed SGLT2i class effect in HFrEF. Together with DAPA-HF, established SGLT2i as mandatory fourth pillar of HFrEF therapy.
Packer M, et al. N Engl J Med. 2020;383(15):1413-1424.
DOI: 10.1056/NEJMoa2022190 →4NEJMMRA in severe HFRALES: Spironolactone in Severe Heart Failure
30% mortality reduction in severe HFrEF; trial stopped early
RALES: Spironolactone in Severe Heart Failure
30% mortality reduction in severe HFrEF; trial stopped early
Population:1,663 adults with severe HFrEF (LVEF ≤35%, NYHA III-IV) on ACEi and loop diuretic.
Intervention: Spironolactone 25 mg daily vs placebo.
Result:30% reduction in all-cause mortality (RR 0.70, 95% CI 0.60-0.82, p<0.001). 35% reduction in HF hospitalization. Trial stopped early at 24 months.
Significance: Established MRA as essential neurohormonal therapy in severe HFrEF. Foundation for COR 1, LOE A recommendation for MRA in HFrEF.
Pitt B, et al. N Engl J Med. 1999;341(10):709-717.
DOI: 10.1056/NEJM199909023411001 →5NEJMMRA in mild HFEMPHASIS-HF: Eplerenone in Mild HFrEF
37% reduction in CV death or HF hospitalization in NYHA II HFrEF
EMPHASIS-HF: Eplerenone in Mild HFrEF
37% reduction in CV death or HF hospitalization in NYHA II HFrEF
Population:2,737 adults with NYHA II HFrEF (LVEF ≤30%, or ≤35% with QRS >130 ms) on ACEi/ARB and beta-blocker.
Intervention: Eplerenone up to 50 mg daily vs placebo.
Result:37% reduction in CV death or HF hospitalization (HR 0.63, 95% CI 0.54-0.74, p<0.001). 24% reduction in all-cause mortality. Trial stopped early.
Significance: Extended MRA benefit from severe (RALES) to mild HFrEF. Confirmed MRA as universal GDMT for all symptomatic HFrEF patients.
Zannad F, et al. N Engl J Med. 2011;364(1):11-21.
DOI: 10.1056/NEJMoa1009492 →Heart Failure with Preserved Ejection Fraction
6NEJMSGLT2i in HFpEFEMPEROR-Preserved: Empagliflozin in HFpEF
21% reduction in CV death or HF hospitalization — first positive RCT in HFpEF
EMPEROR-Preserved: Empagliflozin in HFpEF
21% reduction in CV death or HF hospitalization — first positive RCT in HFpEF
Population:5,988 adults with HFpEF (LVEF >40%) and NYHA II-IV, elevated NT-proBNP.
Intervention: Empagliflozin 10 mg daily vs placebo.
Result:21% reduction in CV death or HF hospitalization (HR 0.79, 95% CI 0.69-0.90, p<0.001). Primarily driven by reduction in HF hospitalizations (29% reduction).
Significance: First positive RCT in HFpEF for a specific drug class. Led to COR 2a recommendation for SGLT2i in HFpEF/HFmrEF.
Anker SD, et al. N Engl J Med. 2021;385(16):1451-1461.
DOI: 10.1056/NEJMoa2107038 →7NEJMSGLT2i in HFpEF/HFmrEFDELIVER: Dapagliflozin in HFpEF and HFmrEF
18% reduction in worsening HF or CV death; confirmed EMPEROR-Preserved
DELIVER: Dapagliflozin in HFpEF and HFmrEF
18% reduction in worsening HF or CV death; confirmed EMPEROR-Preserved
Population:6,263 adults with HF and LVEF >40% (HFpEF and HFmrEF), NYHA II-IV.
Intervention: Dapagliflozin 10 mg daily vs placebo.
Result:18% reduction in worsening HF or CV death (HR 0.82, 95% CI 0.73-0.92, p<0.001). Consistent benefit across LVEF spectrum (>40%), including patients with improved LVEF.
Significance: Confirmed SGLT2i class effect across all LVEF phenotypes. Together with EMPEROR-Preserved, established SGLT2i as first effective therapy for HFpEF.
Solomon SD, et al. N Engl J Med. 2022;387(12):1089-1098.
DOI: 10.1056/NEJMoa2206286 →Device Therapy
8NEJMCRT in mild HFMADIT-CRT: CRT-D in Mild Heart Failure
34% reduction in HF events; greatest benefit with LBBB and QRS ≥150 ms
MADIT-CRT: CRT-D in Mild Heart Failure
34% reduction in HF events; greatest benefit with LBBB and QRS ≥150 ms
Population:1,820 adults with ischemic or non-ischemic cardiomyopathy, LVEF ≤30%, QRS ≥130 ms, NYHA I-II.
Intervention: CRT-D vs ICD alone.
Result:34% reduction in death or HF events (HR 0.66, 95% CI 0.52-0.84, p=0.001). Greatest benefit in LBBB with QRS ≥150 ms (53% reduction). Significant LV reverse remodeling.
Significance:Extended CRT indication to mild HF (NYHA I-II). Identified LBBB and QRS ≥150 ms as strongest predictors of CRT response.
Moss AJ, et al. N Engl J Med. 2009;361(14):1329-1338.
DOI: 10.1056/NEJMoa0906431 →9NEJMCRT in advanced HFCOMPANION: CRT in Advanced Heart Failure
20% reduction in death or hospitalization; CRT-D reduced mortality 36%
COMPANION: CRT in Advanced Heart Failure
20% reduction in death or hospitalization; CRT-D reduced mortality 36%
Population:1,520 adults with NYHA III-IV HF, LVEF ≤35%, QRS ≥120 ms, on optimal medical therapy.
Intervention: CRT-P or CRT-D vs optimal pharmacologic therapy alone.
Result: CRT-P: 20% reduction in death or hospitalization (HR 0.81, p=0.014). CRT-D: 20% reduction in death or hospitalization (HR 0.80, p=0.01) and 36% reduction in mortality (HR 0.64, p=0.003).
Significance: Established CRT benefit in advanced HF with wide QRS. Showed CRT-D superior to CRT-P for mortality reduction.
Bristow MR, et al. N Engl J Med. 2004;350(21):2140-2150.
DOI: 10.1056/NEJMoa032423 →Special Populations and Specific Etiologies
10NEJMH-ISDN in Black patientsA-HeFT: Hydralazine-ISDN in Black Patients with HF
43% mortality reduction; NNT = 25 over 10 months
A-HeFT: Hydralazine-ISDN in Black Patients with HF
43% mortality reduction; NNT = 25 over 10 months
Population: 1,050 self-identified Black adults with NYHA III-IV HFrEF on standard therapy.
Intervention: Fixed-dose hydralazine-isosorbide dinitrate (H-ISDN) vs placebo on top of standard therapy.
Result: 43% reduction in mortality (HR 0.57, p=0.01). 33% reduction in first HF hospitalization. Improved quality of life. Trial stopped early. NNT = 25 over 10 months.
Significance: Led to COR 1, LOE A recommendation for H-ISDN in self-identified Black patients with HFrEF already on optimal GDMT. Also recommended when ACEi/ARB/ARNi are not tolerated.
Taylor AL, et al. N Engl J Med. 2004;351(20):2049-2057.
DOI: 10.1056/NEJMoa042934 →11NEJMCardiac amyloidosisATTR-ACT: Tafamidis in Transthyretin Cardiac Amyloidosis
30% mortality reduction; 32% fewer CV hospitalizations
ATTR-ACT: Tafamidis in Transthyretin Cardiac Amyloidosis
30% mortality reduction; 32% fewer CV hospitalizations
Population: 441 adults with transthyretin-related cardiomyopathy (wild-type or hereditary), NYHA I-III.
Intervention: Tafamidis 80 mg or 20 mg daily vs placebo over 30 months.
Result: 30% reduction in all-cause mortality (HR 0.70, p=0.0006 by Finkelstein-Schoenfeld hierarchical analysis). 32% reduction in CV-related hospitalizations. Slowed decline in 6-minute walk test.
Significance: First disease-modifying therapy for ATTR cardiomyopathy. Led to COR 1, LOE B-R recommendation for tafamidis in ATTR-CM (NYHA I-III).
Maurer MS, et al. N Engl J Med. 2018;379(11):1007-1016.
DOI: 10.1056/NEJMoa1805689 →Acute Decompensated Heart Failure
12NEJMDiuretic dosingDOSE: Diuretic Strategies in Acute Decompensated HF
High-dose IV furosemide produced greater net fluid loss; continuous vs bolus showed no significant difference
DOSE: Diuretic Strategies in Acute Decompensated HF
High-dose IV furosemide produced greater net fluid loss; continuous vs bolus showed no significant difference
Population: 308 adults hospitalized with acute decompensated HF already on oral furosemide.
Intervention:2×2 factorial design: low-dose vs high-dose (2.5× oral dose) IV furosemide, and continuous infusion vs q12h bolus.
Result: No significant difference between continuous and bolus strategies. High-dose furosemide produced greater net fluid loss, weight loss, and dyspnea relief (p=0.06 for global assessment), with transient creatinine increase.
Significance: Informed the guideline recommendation for initial IV diuretic dose of 1-2.5 times the home oral dose. Bolus dosing is acceptable (no need for continuous infusion initially).
Felker GM, et al. N Engl J Med. 2011;364(9):797-805.
DOI: 10.1056/NEJMoa1005419 →Trial summaries are provided for educational purposes. Effect sizes are approximate; consult primary publications for complete data. Source: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Heidenreich PA, et al. Circulation. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063